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Abstract
BACKGROUND—Antihistamines are commonly used during pregnancy. There is little evidence
that they have teratogenic effects, but there are knowledge gaps with respect to newer products, as
well as the relationship between specific antihistamines and specific birth defects.
METHODS—Using the National Birth Defects Prevention Study (1997-2003), the authors
examined associations between maternal use of 14 antihistamines during early pregnancy and 26
isolated major birth defects. A Bayesian analysis incorporating prior knowledge about the
relationships between the antihistamines, birth defects, and measured covariates was conducted.
RESULTS—Of the 364 associations investigated, 24 had 95% posterior intervals excluding 1.0.
All 24 associations were positive; 23 associations were of weak to moderate magnitude (posterior
odds ratio [OR] < 3.0) and one was strong (OR > 6.0) but very imprecise. Of the 24 associations,
20 were with non-cardiac defects. Eight associations involved the antihistamine diphenhydramine.
CONCLUSIONS—The results of this study generally were consistent with no association
between birth defects and antihistamine use during early pregnancy. Several of the findings might
warrant further investigation, although the observed elevated associations should be interpreted in
the context of the number of associations investigated and the analysis of retrospective, self-
reported data.
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INTRODUCTION
Antihistamines, or H1 receptor antagonists, are widely prescribed or taken as over-the-
counter formulations during pregnancy, primarily for the treatment of nausea and vomiting
or relief of cold and allergy symptoms. Antihistamines were first developed in the 1930s,
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and several early products are still in widespread use. The reported prevalence of
antihistamine use ranges from 4–10% during the first trimester, and from 8–15% at any time
during pregnancy (Kallen, 2002; Rubin and others, 1993; Werler and others, 2005).
The epidemiologic literature, which dates back over 40 years, (Heinonen and others, 1977)
provides little support for the teratogenicity of first generation antihistamines, also known as
“nonselective” or “sedating” antihistamines (Briggs and others, 2005). There are, however,
relatively few epidemiologic studies that have examined associations between specific
antihistamines taken during pregnancy and specific birth defects. The National Collaborative
Perinatal Project (NCPP), the first prospective, large-scale investigation of the possible
teratogenic role of medications, reported elevated associations with first trimester use of
brompheniramine and chlorpheniramine and all birth defects combined. Chlorpheniramine
and meclizine were both associated with eye and ear defects. All other NCPP analyses
showed no association between specific antihistamines and birth defects (Heinonen and
others, 1977). The Baltimore-Washington Infant Study, a retrospective case-control study,
found no association between use of any antihistamine medication from 3 months before
pregnancy through the end of the first trimester and risk of all congenital heart defects
(Ferencz and others, 1993). Seto and colleagues’ pooled analysis of 24 studies conducted
during the period 1960–1991 reported a Mantel-Haenszel summary odds ratio (OR) of 0.76
(95% confidence interval [CI]: 0.60, 0.94), indicating a reduced risk of major malformations
(all types of malformations combined) associated with first trimester use of any
antihistamine (Seto and others, 1997). More recently, a publication from the Swedish
Medical Birth Registry raised concerns regarding the possible association between use of the
allergy medication loratadine (a second generation antihistamine) and hypospadias (Källén
and Olausson, 2001). Several subsequent studies, including one based on more recent data
from the Swedish registry, found no association between loratadine and hypospadias
(Centers for Disease Control and Prevention, 2004; Diav-Citrin and others, 2003; Källén and
Olausson, 2006; Moretti and others, 2003; Pedersen and others, 2006a; Pedersen and others,
2006b). The antinauseant Bendectin (which contains the antihistamine, doxylamine
succinate) is one of the most thoroughly studied medications during pregnancy and is not
believed to have teratogenic effects (Boneva and others, 1999; Brent, 2003; Brent, 1995;
Cordero and others, 1981; Elbourne and others, 1985; McKeigue and others, 1994;
Milkovich and van den Berg, 1976; Mitchell and others, 1981; Mitchell and others, 1983;
Shiono and Klebanoff, 1989; Zierler and Rothman, 1985).
Although the body of epidemiologic evidence suggests little or no harmful effect of first-
generation antihistamines on the risk of birth defects, there have been few investigations into
the possible teratogenic effects of the second- and third-generation (also called “selective”
or “non-sedating”) antihistamines that have entered the market relatively recently (e.g.,
fexofenadine). Given the popularity of antihistamines during pregnancy and the gaps in our
knowledge about specific antihistamines in relation to specific birth defects, we conducted a
large-scale analysis of data from a retrospective case-control study to examine a range of
antihistamine products in relation to a range of major malformations. Because there is a
body of literature suggesting that antihistamines are not likely to be teratogenic, we
employed Bayesian analytic methods to incorporate this prior knowledge in the analysis.
MATERIALS AND METHODS
National Birth Defects Prevention Study
The National Birth Defects Prevention Study (NBDPS) is an ongoing, multistate,
population-based case-control study of environmental and genetic risk factors for major
birth defects, incorporating data from 10 birth defects surveillance systems across the United
States and coordinated by the Centers for Disease Control and Prevention (CDC). Detailed
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methods for the NBDPS have been described elsewhere (Yoon and others, 2001). Each year,
Arkansas, California, Georgia, Iowa, Massachusetts, New Jersey (ending in 2002), New
York, North Carolina (beginning in 2003), Texas, and Utah (beginning in 2003) contribute
300 cases from their birth defects surveillance systems and randomly select100 liveborn
controls without birth defects from birth certificate files or delivery logs of birth hospitals.
Medical records of potential cases were reviewed by a team of clinicians and clinical
geneticists to ensure they satisfy the inclusion criteria; infants and fetuses with chromosomal
abnormalities and single-gene disorders are excluded from the study. In addition, cases with
heart defects were confirmed by echocardiography and/or cardiac catheterization, surgery,
or autopsy. Several heart defects were excluded from NBDPS because they were rare,
poorly ascertained in infancy, related to preterm delivery (isolated patent ductus arteriosus
and isolated patent foramen ovale), minor defects of unclear significance, or vascular defects
rather than malformations of the heart (Botto and others, 2007). Computer-assisted
telephone interviews were conducted with mothers from 6 weeks to 24 months after the
estimated date of delivery; interviews were conducted in English or Spanish, as applicable.
Overall participation rates were 72%t among case mothers and 69% among control mothers
during the study period. Women were asked to report medications, vitamins, or supplements
taken for any reason during pregnancy. Estimated dates of use, and the frequency and
duration of use were recorded. Medications were coded using the Slone Epidemiology
Center Drug Dictionary (Kelley and others, 2003), thereby linking the reported substances to
their active ingredients. The NBDPS has been approved by the institutional review boards of
CDC and the participating study centers.
Data Analysis
Outcome Definitions—All cases were classified as having either an isolated defect or
multiple defects. An isolated defect consisted of any of the following: one major defect; one
major defect and one or more minor defects; one or more major defects that affected one
organ system only; or a well-described sequence of related defects without any other
unrelated major defects. Multiple defects were two or more major unrelated defects affecting
different organ systems (Rasmussen and others, 2003). Major defect groups were
categorized by organ system and by organ subgroups when possible. Cases with cardiac
defects received a second classification denoting the complexity of the cardiac defect.
“Simple” cardiac defects were anatomically discrete or a well-recognized single entity (e.g.,
hypoplastic left heart syndrome or tetralogy of Fallot). “Associations” were common,
uncomplicated combinations of cardiac defects (Botto and others, 2007).
Our study population consisted of cases with isolated birth defects and controls born without
birth defects on or after October 1, 1997, with an estimated date of delivery on or before
December 31, 2003. All infants whose mothers had pregestational diabetes (type 1 or type 2)
were excluded. Isolated birth defects for which there were at least 200 cases were included
in this analysis. We considered 11 non-cardiac defects and three aggregated groupings:
neural tube defects, oral clefts and limb deficiencies. We also considered seven simple
cardiac defects, one cardiac defect association, and four aggregated groupings of cardiac
defects: conotruncal defects, left ventricular outflow tract obstructions, right ventricular
outflow tract obstructions, and septal defects.
Antihistamine exposure definitions—Study participants reported use of 54 different
antihistamine agents during the period one month before pregnancy through the end of the
first trimester. We collapsed these 54 components into 14 analytic groups: one group
encompassed the use of any antihistamine, and the other 13 groups were based on the
similarity of formulations and mechanism of action of their antihistamine components::
cetirizine, clemastine, dimenhydrinate, diphenhydramine, doxylamine, hydroxyzine,
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fexofenadine, loratadine, meclizine, pheniramine, promethazine, triprolidine, and not
otherwise specified antihistamine products. Cetirizine, fexofenadine, and loratadine are
second-generation antihistamines. All other groups are first-generation products. Exposure
was defined as any use during the period one month before pregnancy through the end of the
first trimester; the reference group was comprised of infants whose mother did not report the
use of an antihistamine during the same time period.
Covariate definitions—The following covariates were considered potential confounders
of the associations of interest: maternal age (<18, 18–24, 25–29, 30–34, and >35 years),
maternal race or ethnicity (non-Hispanic White, non-Hispanic Black or African American,
Hispanic, and other), maternal education (less than high school, completion of high school,
and more than high school), entry into prenatal care (<10 weeks gestation and >10 weeks
gestation), parity (primiparous and multiparous), household income (<$40,000 and >
$40,000/year), and study center. In addition, periconceptional folic acid use, smoking, and
alcohol intake were dichotomized as any use during the period 1 month before pregnancy
through the first 3 months of pregnancy and no use during the same time window.
Frequentist analyses—We first undertook frequentist analyses (Kleinbaum and Klein,
2002) using multiple logistic regression to estimate adjusted odds ratios and 95% confidence
intervals for the associations between each of the 14 antihistamine groups and the 26 birth
defects under study. All above-mentioned covariates were included in the final adjusted
models.
Bayesian analyses—Following the approach recently detailed by Greenland (Greenland,
2007) we then incorporated prior knowledge about the associations between birth defects
and antihistamines and between birth defects and the other covariates into our analyses.
Because past research has provided little evidence to support the teratogencity of
antihistamines, it seemed reasonable to specify a prior mean log OR = 0 (OR = 1.0) for the
effect of antihistamines. However, because it was unclear how applicable these previous
results were to specific associations between a particular antihistamine and a particular birth
defect, we selected an appropriately large variance (1.125) (95% CI = 0.13, 8.0) around this
prior mean to reflect our uncertainty.
We selected these same prior values (prior OR = 1.0 and 95% CI: 0.13-8.0) for all
independent variables in the model, with the exception of maternal age (30-34 years and >35
years), any smoking during the first trimester, and any alcohol use during the first trimester.
These factors have been associated with an elevated risk of certain birth defects, (Honein
and others, 2007; Reefhuis and Honein, 2004; Romitti and others, 2007) and we specified
prior values to reflect this (mean log OR = 0.693, variance = 1.125, corresponding to a prior
OR = 2.0 and 95% CI: 0.25, 16.00). As described by Greenland (Greenland, 2007), we
incorporated this prior information by adding observations to the dataset. Briefly, for each
independent variable in the logistic regression model, approximately 200,000 observations
were added to the dataset to represent the prior information about the relationship between
that factor and birth defects. An additional variable was also created to denote whether the
record was part of the original (actual) data or prior data. This variable was included in all
regression models. Multivariable logistic regression models were used to estimate Bayesian
posterior odds ratios and 95% posterior intervals based on this augmented dataset. Both the
frequentist and Bayesian analyses were conducted in SAS 9.1.3 (Cary, NC).
Secondary Analyses—After reviewing our results, we conducted secondary analyses of
selected associations to explore potential confounding by two types of conditions: a) nausea
and/or vomiting of pregnancy during the first semester (Boneva and others, 1999); b)
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respiratory infection accompanied by fever, because hyperthermia is a risk factor for
selected birth defects (Li and others, 2007). In addition, because evidence for teratogenicity
has frequently been found among infants with multiple congenital anomalies (MCA)
(Khoury and others, 1994; Khoury and others, 1993), we also analyzed all cases with MCA
as a single group, in relation to the 14 antihistamine exposures.
RESULTS
The frequency of antihistamine use was similar among cases with either an isolated non-
cardiac defect or an isolated cardiac defect and among controls (Tables 1 and 2).
Promethazine, an antinauseant, was the most frequently used antihistamine. Pheniramines
(including chlorpheniramine, brompheniramine, and their derivatives), generally used to
treat cold and allergy symptoms, were the second most common antihistamine components
used. Diphenhydramine, loratadine, and doxylamine were also used by more than 1% of
control mothers. Out of the 364 possible antihistamine–birth defect combinations, 74 (20%)
had no exposed cases.
In analyses conducted before the Bayesian augmentation of the dataset, there were 23
statistically significant associations; after Bayesian augmentation, there were 24 associations
with posterior intervals that excluded 1.0 (Tables 3 and 4). Eighteen of the 24 were found in
both analyses. The six associations that had Bayesian posterior intervals that excluded 1.0
but were not statistically significant before Bayesian augmentation were of “borderline”
significance prior to data augmentation (any antihistamine and cleft lip with or without cleft
palate and craniosynostosis; diphenhydramine and spina bifida, pheniramine and spina
bifida, and promethazine and neural tube defects and ventricular septal defect with atrial
septal defect). The five that were significant before Bayesian augmentation of the dataset but
had posterior intervals that included 1.0 were very imprecise results based on between 3 and
6 exposed cases (meclizine and oral clefts, hydroxyzine and atrial septal defect, and
antihistamine not otherwise specified and spina bifida, cleft lip with or without cleft palate
and ventricular septal defect).
Of the 24 associations, 20 were with non-cardiac defects (Table 3) and four were with
cardiac defects (Table 4). Twenty-three associations were of modest magnitude (OR < 3.0);
the association between meclizine and cleft palate was large, but imprecise (OR = 6.16, 95%
posterior interval: 1.78, 21.33). There was one positive association with a second–generation
product: loratadine and transverse limb deficiencies (OR = 2.04; 95% posterior interval:
1.04, 4.03). Eight of the associations were with exposure to diphenhydramine. These were
for neural tube defects, spina bifida, oral clefts, cleft lip with or without cleft palate,
transverse limb deficiencies, craniosynostosis, gastroschisis, and right ventricular outflow
tract obstruction defects. Risk of spina bifida was associated with five antihistamine
categories: use of any antihistamine, diphenhydramine, doxylamine, pheniramine, and
promethazine. Among the four associations with cardiac defects, two were between
doxylamine and left ventricular outflow tract obstruction defects.
For all 24 results for which the Bayesian posterior interval excluded 1.0, we conducted
secondary analyses to explore potential residual confounding. Results for doxylamine,
promethazine, meclizine, and diphenhydramine were reanalyzed for potential confounding
by the common indication of nausea or vomiting during the first trimester. The pheniramine
and diphenhydramine results were explored for potential confounding by respiratory
infection accompanied by fever during the first trimester. These analyses were largely
insensitive to adjustment by these additional potential confounders in the multivariable
model (data not shown). Lastly, we found no elevated associations between any of the 14
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antihistamine exposure groups and odds of delivering an infant with MCA (n=1365 cases)
(data not shown).
DISCUSSION
We conducted a large-scale analysis to examine a range of antihistamine products in relation
to a range of major malformations and employed Bayesian methods to incorporate our prior
knowledge into the analysis. Overall, the results were consistent with a lack of association of
birth defects with the use of antihistamines during early pregnancy. Our results should be
interpreted with the understanding that we created many statistical models and that several
associations may have resulted by chance. The Bayesian approach was not implemented as a
solution to the problem of multiple comparisons. Rather, the approach was helpful in
controlling estimates based on very small cell counts; five associations that were unstable,
yet statistically significant before Bayesian analysis, now had 95% posterior intervals that
included 1.0. This was a sign that the approach was useful for this purpose. The six
associations that had posterior intervals that excluded 1.0 in the Bayesian analysis that were
not statistically significant before were arguably of “borderline” significance, and can be
considered hypothesis-generating findings. The 18 associations that were found in both the
pre-Bayesian and the Bayesian analyses are potentially more noteworthy, having withstood
the Bayesian adjustment. However these may still be chance findings. Of the 24 associations
with posterior intervals excluding 1.0, 16 were of weak magnitude (OR < 2.0), seven were
of moderate magnitude (OR 2.0 – < 3.0), and one association had an OR ≥3.0 (meclizine
and cleft palate). Eight of the twenty-four associations were with diphenhydramine
exposure. Five of the twenty-four were with spina bifida.
The observed associations with diphenhydramine were unexpected. Diphenhydramine was
one of the first antihistamines sold in the United States (1946); it is still used in several
prescription and over-the-counter medications (Briggs and others, 2005). There is little
evidence that it is teratogenic in animals although non-teratogenic adverse effects in rats
have been reported (Chiavegatto and others, 1997; Sturman and others, 2002). One
epidemiologic study reported increased risk for cleft palate associated with
diphenhydramine use, although this analysis did not adjust for potential confounders and
was based on only 8 exposed cases (Saxen, 1974). This finding has not been replicated in
the epidemiologic literature. We observed an elevated risk associated with cleft lip with or
without cleft palate, but not with cleft palate alone. The modest positive associations
between diphenhydramine exposure and neural tube defects, spina bifida (but not with
anencephaly), transverse limb deficiencies, craniosynostosis, and gastroschisis might
warrant follow-up evaluation but none of them have been reported previously.
Our results for doxylamine were also unanticipated. Doxylamine succinate was an active
ingredient in the antinauseant Bendectin, and is still found in several over-the-counter
products that are used frequently during pregnancy. In 1983, Bendectin was voluntarily
taken out of production following the filing of several hundred lawsuits alleging its
teratogenicity and the adverse media attention associated with the litigation. The vast
majority of epidemiologic studies of Bendectin and birth defects, including all prospective
analyses, as well as several reviews and meta-analyses of the literature have reported null
results or inverse associations (Boneva and others, 1999; Brent, 2003; Brent, 1995; Cordero
and others, 1981; Elbourne and others, 1985; McKeigue and others, 1994; Milkovich and
van den Berg, 1976; Mitchell and others, 1981; Mitchell and others, 1983; Shiono and
Klebanoff, 1989; Zierler and Rothman, 1985). There have been only a few exceptions
(Aselton and others, 1984; Eskenazi and Bracken, 1982; Golding and others, 1983; Rothman
and others, 1979) based on restrospective studies. The elevated risks that we observed for
doxylamine in relation to hypoplastic left heart syndrome, left ventricular outflow tract
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obstruction defects, spina bifida, and neural tube defects were therefore not anticipated
given the extensive epidemiologic data suggesting the safety of doxylamine in relation to
birth defects overall, as well as several specific birth defect phenotypes, including neural
tube defects. Regarding left ventricular outflow tract obstructions, one study reported no
association with hypoplastic left heart syndrome in the context of a primary analysis of
nausea during pregnancy (Boneva and others, 1999).
The associations observed between pheniramine (which included medications containing
either brompheniramine or chlorpheniramine) and spina bifida and cleft lip with or without
cleft palate have not been previously reported and there is no evidence in the literature to
suggest its teratogenicity. The NCPP reported associations between brompheniramine and
chlorpheniramine and all birth defects, but not specifically with clefts (Heinonen and others,
1977). Meclizine, which is teratogenic in rats and is known to induce cleft palate at 25–50
times the human doses, (King, 1963) has not been reported to cause human birth defects
(Källén and Mottet, 2003). The observed association between meclizine and cleft palate was
based on five exposed cases and was our most imprecise result. Promethazine, the most
commonly used antihistamine among NBDPS participants, was nearly always prescribed for
morning sickness (82% of users). The associations with spina bifida, all neural tube defects
as a group, and ventricular septal defects with atrial septal defects have never been reported
in the literature and may be chance results. Our analyses corroborated the lack of association
between loratadine and hypospadias that had been reported recently in the literature (Centers
for Disease Control and Prevention, 2004; Diav-Citrin and others, 2003; Källén and
Olausson, 2006; Moretti and others, 2003; Pedersen and others, 2006a; Pedersen and others,
2006b).
We stabilized imprecise effect estimates by using a Bayesian analysis with a dataset
augmented with additional observations to represent prior data. Because our prior estimates
for the mean and variance for the effect of antihistamine exposure (OR = 1.0; 95% CI: 0.13,
8.0) and the other independent variables in the multivariable models were conservative (i.e.
very wide confidence interval around the prior mean), the overall effect of the Bayesian
adjustment was small. The Bayesian adjustment, however, had a more pronounced effect on
initially unstable effect estimates with very large confidence intervals because of few
exposed cases. These estimates were stabilized substantially after data augmentation. For
example, the association between meclizine use and isolated cleft palate (five exposed cases)
before data augmentation was large and imprecise (frequentist OR = 12.69; 95% CI: 2.89,
55.66). After data augmentation, these results were more precise and pulled toward the null
(posterior OR = 6.16; 95% posterior interval: 1.78, 21.33).
The NBDPS provided an opportunity to look at more birth defect phenotypes in relation to
more types of antihistamines than ever previously reported in the literature. A strength of
our study was the detailed classification of birth defects by clinical geneticists, which
allowed for analyses of etiologically similar outcome groups. In addition, our focus on
isolated phenotypes was intended to add to this homogeneity within outcome groupings and
reduced the “double counting” of cases. Yet despite these strengths, there were several
limitations that pertain specifically to the medication data. First, we were unable to consider
over-the-counter versus prescription status in our analyses. It is possible that over-the-
counter medication use was perceived as more casual than prescription drug use and
recollection of use might have varied between these two types or over time. This would be
particularly true if a medication became available over-the-counter during the course of the
study. Loratadine is one example of this. In November 2002, the FDA approved loratadine
for marketing over the counter. In NBDPS data, the first pregnancies potentially affected by
this transition were delivered in late 2003; we saw no evidence of increased use from 2002
to 2003. Second, some mothers reported the use of an antihistamine on an “as needed” basis.
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“As needed” use was more common for some antihistamine types than for others, but
sensitivity analyses excluding “as needed” exposures did not show differences in the
associations with birth defects. Third, antihistamine products can have more than one active
ingredient, such as a fever reducer, decongestant, or cough suppressant. Our analyses did not
distinguish between use of products that contained only the antihistamine and those that
contained the antihistamine in combination with other drugs. Fourth, although we conducted
several secondary analyses to evaluate the sensitivity of our results to potential confounding
by indication, these analyses were not comprehensive. Antihistamines have several primary
uses; in our data, approximately 40% of episodes were indicated for a reported respiratory
illness and about 20% for nausea or vomiting, or both, during pregnancy. Because an
additional 30% of women did not report an indication for their antihistamine medication use
and the remaining 10% reported a wide range of medical indications, a substantial number
of observations were excluded from these analyses because of no or uncommon indications.
Some indications, such as for seasonal allergies, could not be explicitly reported in these
data, and might (or might not) have been captured by the “respiratory illness” indication.
We were also unable to evaluate potential exposure misclassification due to biased or
incorrect recall. Even though all interviews were conducted within 24 months of delivery,
the time lag, or perhaps an intervening pregnancy, might have led to inaccurate recall of
maternal antihistamine use. The average time between delivery and interview was longer for
case mothers than for control mothers (11 months versus 9 months); however, analyses
stratifying by time between expected date of delivery and date of interview (<12 months,
12–<18 months, and >18 months) did not suggest that the associations observed were due to
recall bias. In addition, we could not preclude the possibility of residual confounding in
these data by either unmeasured or poorly measured covariates. Finally, it is possible that
some antihistamines are associated with birth defects that are not included in the NBDPS.
Even though our study included more exposed case and control infants than most previous
studies, the data were sparse for some antihistamine exposures, especially the second-
generation products. Our analytic approach mitigated this problem because it allowed us to
shrink and stabilize several large, but very imprecise estimates in multivariable models.
However, our approach did not eliminate the possibility of type 1 errors (false positives).
The results of our study were consistent with no large increased risk for birth defects
associated with antihistamine use during early pregnancy. The observed elevated
associations should be interpreted in the context of the number of associations investigated
and the analysis of retrospective, self-reported data.
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Table 3
Adjusted Odds Ratios and 95% Confidence Intervals and Adjusted Posterior Odds Ratios and 95% Posterior
Intervals For Associations Between Antihistamine Use and Isolated Non-Cardiac Birth Defects, Before and
After Bayesian Data Augmentation, National Birth Defects Prevention Study, 1997-2003
Birth Defect Analysis*
Any
Antihistamine Cetirizine Clemastine Dimenhydrinate Diphenhydramine Doxylamine Fexofenadine
Neural tube defects Non-Bayesian 1.35 (1.06,1.73) 0.50 (0.12,2.11) 0.96 (0.11,8.15) -- 1.72 (1.03,2.87) 2.09 (1.20,3.62) 1.28 (0.52,3.14)
Bayesian 1.54 (1.20,1.98) 0.64 (0.21,1.96) 1.03 (0.23,4.68) -- 1.95 (1.16,3.27) 2.32 (1.33,4.03) 1.29 (0.55,3.05)
 Anencephalus Non-Bayesian 1.18 (0.77,1.81) 0.71 (0.09,5.39) -- -- 1.49 (0.63,3.55) 1.73 (0.67,4.47) 1.23 (0.28,5.29)
Bayesian 1.29 (0.85,1.97) 0.85 (0.21,3.49) -- -- 1.50 (0.66,3.41) 1.68 (0.69,4.13) 1.14 (0.33,3.88)
 Spina bifida Non-Bayesian 1.45 (1.07,1.97) -- 1.86 (0.22,16.10) -- 1.83 (0.97,3.44) 2.21 (1.12,4.33) 1.49 (0.51,4.33)
Bayesian 1.61 (1.18,2.18) -- 1.38 (0.28,6.82) -- 1.94 (1.04,3.63) 2.27 (1.17,4.42) 1.52 (0.56,4.11)
Anotia / Microtia Non-Bayesian 1.21 (0.73,2.01) -- -- 3.10 (0.37,26.29) 1.48 (0.52,4.26) 1.67 (0.56,4.96) --
Bayesian 1.30 (0.79,2.15) -- -- 1.81 (0.33,10.04) 1.45 (0.54,3.87) 1.60 (0.58,4.43) --
Oral clefts Non-Bayesian 1.07 (0.89,1.30) 1.23 (0.59,2.54) 1.29 (0.32,5.23) 1.08 (0.27,4.22) 1.58 (1.07,2.34) 1.21 (0.73,1.99) 1.23 (0.62,2.46)
Bayesian 1.23 (1.00,1.50) 1.17 (0.58,2.36) 1.31 (0.40,4.32) 1.28 (0.39,4.22) 1.77 (1.18,2.65) 1.43 (0.85,2.38) 1.51 (0.76,3.00)
 Cleft palate Non-Bayesian 0.95 (0.69,1.29) 1.60 (0.60,4.30) Not estimable 2.16 (0.44,10.60) 1.26 (0.66,2.43) 1.44 (0.70,2.99) 1.27 (0.44,3.70)
Bayesian 1.03 (0.75,1.41) 1.46 (0.58,3.64) 0.61 (0.11,3.41) 1.85 (0.47,7.31) 1.34 (0.71,2.54) 1.47 (0.73,2.98) 1.34 (0.50,3.56)
 Cleft lip w/wo cleft palate Non-Bayesian 1.14 (0.91,1.42) 1.02 (0.41,2.54) 2.09 (0.52,8.52) 0.52 (0.06,4.26) 1.73 (1.12,2.68) 1.12 (0.62,2.02) 1.24 (0.56,2.77)
Bayesian 1.30 (1.03,1.63) 1.02 (0.44,2.38) 1.85 (0.55,6.23) 0.77 (0.18,3.23) 1.91 (1.23,2.98) 1.30 (0.72,2.36) 1.47 (0.68,3.21)
Anorectal atresia Non-Bayesian 0.63 (0.36,1.11) -- -- -- 0.57 (0.14,2.35) 0.75 (0.18,3.13) 1.56 (0.36,6.68)
Bayesian 0.68 (0.40,1.17) -- -- -- 0.68 (0.22,2.06) 0.80 (0.25,2.54) 1.38 (0.39,4.84)
Hypospadias Non-Bayesian 1.07 (0.81,1.41) 0.85 (0.33,2.20) 0.48 (0.05,4.68) -- 1.23 (0.63,2.42) 1.65 (0.81,3.34) 1.60 (0.67,3.83)
Bayesian 1.09 (0.82,1.45) 0.86 (0.36,2.05) 0.73 (0.16,3.29) -- 1.28 (0.66,2.49) 1.63 (0.81,3.27) 1.50 (0.67,3.39)
Limb deficiencies Non-Bayesian 1.22 (0.87,1.71) 0.52 (0.07,3.88) -- Not estimable 1.74 (0.90,3.34) 1.06 (0.42,2.69) 0.91 (0.21,3.86)
Bayesian 1.30 (0.93,1.82) 0.71 (0.18,2.75) -- 0.67 (0.11,3.92) 1.77 (0.93,3.35) 1.12 (0.47,2.65) 0.98 (0.30,3.23)
 Transverse limb deficiencies Non-Bayesian 1.62 (1.11,2.38) -- -- -- 2.30 (1.11,4.73) 1.04 (0.32,3.39) 1.50 (0.35,6.48)
Bayesian 1.71 (1.17,2.50) -- -- -- 2.23 (1.10,4.53) 1.07 (0.38,3.03) 1.34 (0.38,4.67)
Craniosynostosis Non-Bayesian 1.31 (0.98,1.75) 0.65 (0.15,2.79) 1.23 (0.14,10.57) -- 2.48 (1.48,4.13) 1.05 (0.47,2.36) 0.99 (0.30,3.33)
Bayesian 1.38 (1.03,1.85) 0.72 (0.23,2.29) 1.15 (0.25,5.30) -- 2.47 (1.48,4.10) 1.05 (0.49,2.23) 1.02 (0.36,2.92)
Diaphragmatic hernia Non-Bayesian 1.05 (0.71,1.56) 0.55 (0.07,4.10) -- -- 1.35 (0.57,3.16) 1.10 (0.39,3.10) 0.54 (0.07,4.02)
Bayesian 1.11 (0.75,1.65) 0.74 (0.19,2.87) -- -- 1.33 (0.60,2.99) 1.13 (0.44,2.88) 0.75 (0.19,2.94)
Gastroschisis Non-Bayesian 1.17 (0.82,1.68) 1.18 (0.25,5.59) -- 1.07 (0.12,9.34) 2.02 (1.04,3.92) 1.57 (0.72,3.42) 1.11 (0.25,5.00)
Bayesian 1.26 (0.87,1.82) 1.03 (0.29,3.66) -- 1.28 (0.26,6.21) 1.99 (1.03,3.83) 1.61 (0.75,3.43) 1.16 (0.33,4.08)





Neural tube defects Non-Bayesian -- 1.13 (0.63,2.03) 3.48 (0.57,21.27) 3.14 (0.80,12.28) 1.21 (0.71,2.06) 1.41 (0.90,2.20) 1.08 (0.24,4.90)
Bayesian -- 1.19 (0.67,2.13) 1.68 (0.39,7.27) 2.08 (0.61,7.10) 1.36 (0.80,2.32) 1.63 (1.04,2.54) 0.99 (0.29,3.44)
 Anencephalus Non-Bayesian -- 1.60 (0.67,3.79) -- Not estimable 0.67 (0.21,2.16) 1.01 (0.45,2.26) 1.54 (0.19,12.42)
Bayesian -- 1.56 (0.68,3.54) -- 0.73 (0.12,4.56) 0.79 (0.29,2.16) 1.17 (0.55,2.50) 1.21 (0.26,5.61)
 Spina bifida Non-Bayesian -- 0.80 (0.34,1.87) 5.64 (0.91,35.09) 5.52 (1.42,21.47) 1.68 (0.94,3.01) 1.81 (1.07,3.05) 0.95 (0.12,7.48)
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Bayesian -- 0.85 (0.39,1.87) 2.21 (0.50,9.75) 3.04 (0.86,10.74) 1.86 (1.04,3.33) 1.99 (1.18,3.35) 0.96 (0.22,4.12)
Anotia / Microtia Non-Bayesian -- 0.87 (0.26,2.87) 4.81 (0.46,50.54) 3.93 (0.45,34.50) 0.28 (0.04,2.08) 1.80 (0.62,5.23) --
Bayesian -- 0.90 (0.32,2.55) 1.65 (0.30,9.00) 1.74 (0.32,9.51) 0.50 (0.14,1.76) 1.84 (0.67,5.04) --
Oral clefts Non-Bayesian 1.31 (0.31,5.56) 0.56 (0.32,0.97) 4.62 (1.15,18.67) 2.00 (0.65,6.20) 1.26 (0.87,1.82) 0.73 (0.48,1.11) 0.69 (0.19,2.47)
Bayesian 1.20 (0.35,4.17) 0.59 (0.34,1.02) 3.14 (0.93,10.54) 1.53 (0.54,4.34) 1.47 (1.00,2.16) 0.85 (0.56,1.30) 0.79 (0.27,2.35)
 Cleft palate Non-Bayesian -- 0.41 (0.15,1.12) 12.69 (2.89,55.66) -- 0.73 (0.36,1.47) 0.51 (0.23,1.11) --
Bayesian -- 0.48 (0.20,1.14) 6.16 (1.78,21.33) -- 0.80 (0.41,1.55) 0.63 (0.31,1.30) --
 Cleft lip w/wo cleft palate Non-Bayesian 1.94 (0.46,8.29) 0.64 (0.34,1.19) 1.11 (0.11,10.93) 3.15 (1.01,9.81) 1.54 (1.04,2.30) 0.84 (0.53,1.34) 1.13 (0.31,4.03)
Bayesian 1.57 (0.45,5.54) 0.68 (0.37,1.25) 0.78 (0.17,3.63) 2.20 (0.77,6.31) 1.83 (1.21,2.76) 0.97 (0.61,1.55) 1.17 (0.38,3.58)
Anorectal atresia Non-Bayesian -- 1.93 (0.87,4.30) -- -- 0.22 (0.03,1.60) 0.32 (0.08,1.31) --
Bayesian -- 1.76 (0.81,3.82) -- -- 0.43 (0.13,1.48) 0.48 (0.16,1.39) --
Hypospadias Non-Bayesian -- 1.25 (0.69,2.27) 1.09 (0.07,16.47) 0.70 (0.17,2.97) 1.34 (0.76,2.36) 0.58 (0.30,1.16) 0.21 (0.02,1.76)
Bayesian -- 1.24 (0.69,2.23) 0.98 (0.19,5.06) 0.78 (0.24,2.52) 1.37 (0.78,2.42) 0.63 (0.33,1.20) 0.43 (0.11,1.64)
Limb deficiencies Non-Bayesian 5.02 (0.95,26.42) 1.58 (0.82,3.03) -- 1.15 (0.14,9.47) 1.03 (0.49,2.15) 0.90 (0.41,1.98) 0.94 (0.12,7.31)
Bayesian 2.47 (0.58,10.54) 1.56 (0.82,2.95) -- 1.04 (0.23,4.63) 1.08 (0.53,2.18) 1.03 (0.49,2.16) 0.98 (0.23,4.23)
 Transverse limb deficiencies Non-Bayesian 3.97 (0.45,35.35) 2.16 (1.08,4.30) -- 1.62 (0.19,13.58) 1.04 (0.42,2.61) 1.70 (0.76,3.80) 1.53 (0.20,11.98)
Bayesian 1.75 (0.32,9.57) 2.04 (1.04,4.03) -- 1.24 (0.26,5.82) 1.10 (0.47,2.57) 1.75 (0.81,3.81) 1.26 (0.27,5.85)
Craniosynostosis Non-Bayesian -- 1.18 (0.60,2.33) -- -- 1.42 (0.79,2.54) 1.15 (0.65,2.03) 1.46 (0.32,6.64)
Bayesian -- 1.16 (0.60,2.23) -- -- 1.50 (0.85,2.67) 1.24 (0.71,2.17) 1.28 (0.36,4.56)
Diaphragmatic hernia Non-Bayesian Not estimable 0.95 (0.38,2.39) 5.18 (0.51,52.09) 1.91 (0.23,15.60) 0.80 (0.32,2.00) 1.20 (0.59,2.45) --
Bayesian 0.79 (0.12,5.15) 0.95 (0.41,2.21) 1.82 (0.32,10.22) 1.31 (0.27,6.24) 0.88 (0.38,2.02) 1.32 (0.66,2.62) --
Gastroschisis Non-Bayesian -- 0.98 (0.40,2.41) -- -- 0.40 (0.12,1.30) 1.66 (0.91,3.05) --
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Table 4
Adjusted Odds Ratios and 95% Confidence Intervals and Adjusted Posterior Odds Ratios and 95% Posterior
Intervals For Associations Between Antihistamine Use and Isolated Cardiac Birth Defects, Before and After
Bayesian Data Augmentation, National Birth Defects Prevention Study, 1997-2003
Birth Defect Analysis*
Any
Antihistamine Cetirizine Clemastine Dimenhydrinate Diphenhydramine Doxylamine Fexofenadine
Conotruncal defects Non-Bayesian 1.08 (0.83,1.40) 0.80 (0.24,2.71) 0.90 (0.11,7.58) 1.47 (0.30,7.11) 0.98 (0.53,1.83) 1.45 (0.76,2.75) 1.53 (0.66,3.56)
Bayesian 1.15 (0.89,1.51) 0.85 (0.30,2.39) 0.99 (0.22,4.43) 1.35 (0.36,5.05) 1.02 (0.56,1.86) 1.54 (0.82,2.89) 1.62 (0.72,3.66)
 Tetralogy of Fallot Non-Bayesian 1.16 (0.83,1.63) 0.50 (0.07,3.76) -- Not estimable 1.11 (0.50,2.46) 1.65 (0.73,3.71) 0.83 (0.19,3.53)
Bayesian 1.22 (0.87,1.71) 0.69 (0.18,2.63) -- 0.69 (0.12,4.12) 1.14 (0.54,2.41) 1.65 (0.76,3.59) 0.93 (0.28,3.02)
 D-Transposition of the
great arteries Non-Bayesian 1.01 (0.65,1.56) 0.83 (0.11,6.35) 3.39 (0.39,29.17) 4.01 (0.80,19.99) 0.72 (0.22,2.32) 1.66 (0.65,4.26) 1.35 (0.31,5.81)




Non-Bayesian 1.07 (0.80,1.43) 0.30 (0.04,2.22) 1.07 (0.13,9.03) 1.68 (0.35,8.17) 0.94 (0.46,1.91) 1.94 (1.06,3.56) 1.14 (0.39,3.29)
Bayesian 1.15 (0.86,1.54) 0.49 (0.14,1.74) 1.11 (0.24,5.09) 1.45 (0.39,5.43) 1.01 (0.51,1.98) 1.99 (1.10,3.61) 1.10 (0.42,2.89)
 Hypoplastic left heart
syndrome Non-Bayesian 1.10 (0.71,1.69)
-- 2.62 (0.30,22.47) -- 1.29 (0.51,3.26) 3.05 (1.40,6.61) --
Bayesian 1.16 (0.76,1.78) -- 1.60 (0.31,8.36) -- 1.28 (0.54,3.04) 2.78 (1.30,5.94) --
 Coarctation of the aorta Non-Bayesian 1.10 (0.69,1.73) -- -- 2.01 (0.23,17.30) 0.85 (0.26,2.77) 1.86 (0.72,4.79) 2.04 (0.60,6.90)




Non-Bayesian 1.00 (0.74,1.34) 0.86 (0.25,2.87) 1.38 (0.16,11.75) -- 1.94 (1.14,3.32) 0.71 (0.28,1.81) 0.29 (0.04,2.19)
Bayesian 1.06 (0.79,1.43) 0.92 (0.32,2.60) 1.22 (0.26,5.75) -- 1.94 (1.14,3.29) 0.76 (0.33,1.77) 0.50 (0.14,1.80)
 Pulmonary valve stenosis Non-Bayesian 0.95 (0.68,1.34) 1.03 (0.30,3.47) 1.98 (0.22,17.40) -- 1.54 (0.79,2.98) 0.54 (0.17,1.77) 0.39 (0.05,2.94)
Bayesian 1.01 (0.72,1.41) 1.05 (0.36,3.02) 1.39 (0.28,6.86) -- 1.48 (0.78,2.82) 0.64 (0.24,1.73) 0.59 (0.16,2.20)
Septal defects Non-Bayesian 1.09 (0.88,1.33) 0.47 (0.16,1.39) 0.49 (0.06,4.24) 0.80 (0.16,3.96) 0.99 (0.61,1.61) 1.31 (0.76,2.26) 1.03 (0.46,2.31)
Bayesian 1.15 (0.94,1.42) 0.53 (0.21,1.35) 0.74 (0.17,3.14) 0.88 (0.25,3.14) 0.99 (0.61,1.61) 1.37 (0.79,2.39) 1.06 (0.49,2.30)
Ventricular septal defect −
Perimembranous Non-Bayesian 1.15 (0.87,1.53) Not estimable 1.25 (0.14,10.77)
-- 1.61 (0.90,2.88) 1.22 (0.56,2.62) 0.91 (0.27,3.07)
Bayesian 1.21 (0.91,1.60) 0.30 (0.07,1.26) 1.17 (0.25,5.50) -- 1.56 (0.88,2.78) 1.21 (0.58,2.53) 1.00 (0.35,2.85)
Atrial septal defect −
Ostium secundum Non-Bayesian 1.00 (0.73,1.37) 1.11 (0.32,3.89)
-- 2.00 (0.39,10.20) 0.59 (0.25,1.39) 1.01 (0.42,2.44) 1.70 (0.63,4.58)
Bayesian 1.05 (0.77,1.44) 1.02 (0.35,3.01) -- 1.56 (0.40,6.03) 0.61 (0.28,1.33) 1.03 (0.45,2.35) 1.57 (0.62,3.97)
Ventricular septal defect +
Atrial septal defect Non-Bayesian 1.23 (0.82,1.83) 0.63 (0.08,4.81) 2.31 (0.26,20.29) 2.15 (0.26,17.96) 1.34 (0.52,3.41) 1.81 (0.70,4.68) 0.63 (0.08,4.78)
Bayesian 1.30 (0.88,1.94) 0.80 (0.20,3.20) 1.54 (0.30,7.97) 1.48 (0.29,7.46) 1.24 (0.52,2.96) 1.65 (0.67,4.06) 0.80 (0.20,3.21)
Birth Defect
Analysis* Hydroxyzine Loratadine Meclizine AntihistamineNot Otherwise
Specified
Pheniramine† Promethazine Triprolidine
Conotruncal defects Non-Bayesian 1.11 (0.13,9.73) 1.32 (0.77,2.27) -- 1.59 (0.33,7.61) 0.89 (0.50,1.58) 0.95 (0.56,1.61) --
Bayesian 0.91 (0.20,4.08) 1.35 (0.79,2.31) -- 1.26 (0.35,4.56) 0.94 (0.54,1.65) 1.09 (0.64,1.84) --
 Tetralogy of Fallot Non-Bayesian -- 1.34 (0.66,2.72) -- 1.60 (0.20,13.09) 1.05 (0.52,2.12) 1.52 (0.84,2.74) --
Bayesian -- 1.31 (0.66,2.60) -- 1.21 (0.26,5.64) 1.10 (0.56,2.16) 1.65 (0.92,2.94) --
 D-Transposition of the
great arteries
Non-Bayesian 3.20 (0.36,28.13) 1.31 (0.56,3.08) -- 2.30 (0.28,18.96) 0.56 (0.18,1.81) 0.50 (0.15,1.61) --




Non-Bayesian -- 1.08 (0.55,2.12) -- 2.18 (0.45,10.56) 0.99 (0.53,1.83) 0.86 (0.47,1.57) 1.10 (0.24,4.96)
Bayesian -- 1.11 (0.58,2.13) -- 1.60 (0.42,6.12) 1.04 (0.57,1.88) 0.97 (0.54,1.73) 1.04 (0.30,3.56)
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Birth Defect
Analysis* Hydroxyzine Loratadine Meclizine AntihistamineNot Otherwise
Specified
Pheniramine† Promethazine Triprolidine
 Hypoplastic left heart
syndrome
Non-Bayesian -- 0.54 (0.13,2.22) -- 2.89 (0.35,24.19) 1.01 (0.40,2.54) 0.68 (0.27,1.72) 1.23 (0.16,9.67)
Bayesian -- 0.66 (0.22,2.01) -- 1.53 (0.30,7.78) 1.08 (0.46,2.52) 0.80 (0.35,1.85) 1.07 (0.24,4.74)
 Coarctation of the aorta Non-Bayesian -- 1.41 (0.56,3.59) -- 2.97 (0.35,25.36) 0.67 (0.21,2.15) 1.09 (0.43,2.77) 1.39 (0.18,10.94)




Non-Bayesian 1.71 (0.19,15.11) 0.44 (0.16,1.21) -- 1.01 (0.12,8.22) 0.86 (0.46,1.63) 1.23 (0.75,2.02) 1.08 (0.24,4.89)
Bayesian 1.30 (0.27,6.37) 0.51 (0.21,1.21) -- 0.98 (0.22,4.25) 0.93 (0.50,1.71) 1.38 (0.85,2.25) 1.01 (0.30,3.46)
 Pulmonary valve stenosis Non-Bayesian 2.62 (0.28,24.29) 0.30 (0.07,1.25) -- 1.34 (0.16,11.08) 0.93 (0.46,1.88) 1.22 (0.71,2.10) 1.41 (0.31,6.47)
Bayesian 1.50 (0.29,7.70) 0.42 (0.15,1.20) -- 1.12 (0.25,5.09) 0.99 (0.51,1.94) 1.35 (0.80,2.31) 1.17 (0.33,4.13)
Septal defects Non-Bayesian 3.13 (0.79,12.33) 1.15 (0.71,1.86) 0.87 (0.09,8.51) 3.00 (0.94,9.53) 1.04 (0.69,1.58) 1.15 (0.81,1.65) 0.53 (0.12,2.42)
Bayesian 2.33 (0.70,7.79) 1.20 (0.74,1.93) 0.80 (0.18,3.61) 2.38 (0.83,6.83) 1.11 (0.73,1.67) 1.27 (0.89,1.82) 0.62 (0.19,2.01)
Ventricular septal defect −
Perimembranous
Non-Bayesian 1.74 (0.19,15.92) 0.94 (0.46,1.91) 2.83
(0.28,28.09)
3.96 (1.01,15.57) 1.03 (0.58,1.85) 1.28 (0.79,2.08) 1.12 (0.24,5.24)
Bayesian 1.30 (0.27,6.35) 0.95 (0.48,1.88) 1.41 (0.28,7.19) 2.55 (0.74,8.76) 1.09 (0.62,1.92) 1.38 (0.86,2.24) 1.02 (0.29,3.57)
Atrial septal defect −
Ostium secundum
Non-Bayesian 5.13 (1.15,22.84) 1.10 (0.51,2.35) -- 1.78 (0.20,15.47) 0.93 (0.49,1.79) 1.21 (0.73,2.00) --
Bayesian 2.93 (0.78,11.03) 1.12 (0.54,2.33) -- 1.28 (0.26,6.19) 1.01 (0.54,1.89) 1.30 (0.79,2.15) --
Ventricular septal defect +
Atrial septal
defect
Non-Bayesian -- 0.71 (0.22,2.29) -- -- 0.52 (0.16,1.68) 1.85 (0.99,3.45) 2.52 (0.55,11.63)
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